RPL35A是参与胃癌发生发展的关键启动子

2021年9月，中国人民解放军总医院**医疗中心普外科高级科(Senior Department of General Surgery, The First Medical Center of Chinese, PLA General Hospital, Fuxin Road, No. 28, Haidian District,Beijing 100853, China) Canrong Lu老师研究团队在《Cancer Cell International》上发表论文：

“RPL35A is a key promotor involved in the development and progression of gastric cancer”

“RPL35A是参与胃癌发生发展的关键启动子”

Abstract：

Background: RPL35A has been reported to work as a biomarker in tumor angiogenesis. However, little work has been performed on the expression level and functional importance of RPL35A in gastric cancer (GC).

Methods: The protein expression level of RPL35A was detected by immunohistochemical staining and western blot analysis. The Celigo cell counting assay was used to assess cell proliferation. Both the wound healing assay and the transwell assay were conducted to evaluate cell migration. Flow cytometric analysis was utilized to detect cell apoptosis and cell cycle. A mouse xenograft model was constructed for in vivo experiments.

Results: The results demonstrated that RPL35A expression was abundantly up-regulated in GC and positively related to tumor infiltrate. In addition, RPL35A knockdown could significantly suppress cell proliferation, migration, enhance apoptosis and arrest cell cycle. The in vivo study also verified the inhibitory effects of RPL35A knockdown on GC tumorigenesis.

Conclusions: The above mentioned results indicated that the knockdown of RPL35A might be a considerable therapeutic strategy for the treatment of gastric cancer.

摘要：

背景:RPL35A已被报道为肿瘤血管生成的生物标志物。然而，关于RPL35A在胃癌(GC)中的表达水平及其功能重要性的研究很少。

方法:采用免疫组化染色和western blot方法检测RPL35A蛋白表达水平。采用Celigo细胞计数法评估细胞增殖情况。采用伤口愈合实验和transwell实验来评估细胞迁移。流式细胞术检测细胞凋亡和细胞周期。建立小鼠异种移植物模型进行体内实验。

结果:结果显示RPL35A在胃癌中表达量显著上调，与肿瘤浸润呈正相关。RPL35A敲低可显著抑制细胞增殖、迁移、促进细胞凋亡、阻滞细胞周期。体内研究也证实了RPL35A敲低对GC肿瘤发生的抑制作用。

结论:上述结果提示，下调RPL35A可能是治疗胃癌的一种有效的治疗策略。

该论文中，AGS和MGC-803细胞的体外培养是使用Ausbian特级胎牛血清完成的。欲了解或购买Ausbian特级胎牛血清可以联系北京缔一生物400-166-8600.